- Home
- GALT vs NAVI Comparison
GALT vs NAVI Comparison
Compare GALT & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- NAVI
- Stock Information
- Founded
- GALT 2000
- NAVI 1973
- Country
- GALT United States
- NAVI United States
- Employees
- GALT N/A
- NAVI N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- NAVI Investment Bankers/Brokers/Service
- Sector
- GALT Health Care
- NAVI Finance
- Exchange
- GALT Nasdaq
- NAVI Nasdaq
- Market Cap
- GALT 86.0M
- NAVI 1.2B
- IPO Year
- GALT N/A
- NAVI N/A
- Fundamental
- Price
- GALT $1.36
- NAVI $13.14
- Analyst Decision
- GALT Hold
- NAVI Hold
- Analyst Count
- GALT 1
- NAVI 7
- Target Price
- GALT N/A
- NAVI $13.64
- AVG Volume (30 Days)
- GALT 177.8K
- NAVI 724.5K
- Earning Date
- GALT 05-19-2025
- NAVI 04-30-2025
- Dividend Yield
- GALT N/A
- NAVI 4.92%
- EPS Growth
- GALT N/A
- NAVI N/A
- EPS
- GALT N/A
- NAVI 0.52
- Revenue
- GALT N/A
- NAVI $699,000,000.00
- Revenue This Year
- GALT N/A
- NAVI N/A
- Revenue Next Year
- GALT N/A
- NAVI N/A
- P/E Ratio
- GALT N/A
- NAVI $24.29
- Revenue Growth
- GALT N/A
- NAVI N/A
- 52 Week Low
- GALT $0.73
- NAVI $10.53
- 52 Week High
- GALT $3.41
- NAVI $16.97
- Technical
- Relative Strength Index (RSI)
- GALT 49.34
- NAVI 60.79
- Support Level
- GALT $1.26
- NAVI $12.53
- Resistance Level
- GALT $1.63
- NAVI $13.05
- Average True Range (ATR)
- GALT 0.12
- NAVI 0.42
- MACD
- GALT 0.02
- NAVI 0.17
- Stochastic Oscillator
- GALT 35.00
- NAVI 93.13
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.